PNV 0.87% $2.28 polynovo limited

Ann: 1H FY23 Results Presentation, page-64

  1. 7,779 Posts.
    lightbulb Created with Sketch. 1337
    Could easily mean that it is being used for smaller wounds, which would bring less revenue per patient, though may mean it is being used more frequently for different indications.

    The important thing, imo, will the the number of facilities purchasing our product, and the number of different surgeons using our product.

    Increase in facilities using our product means more facilities becoming more comfortable with its use, familiar with the brand name, and more familiar with its benefits (shortened hospital stay, for example).

    Increase in surgeons using our product means people becoming more familiar with how the product works, more teams pushing the envelope with its indications and it's potential, and more case studies being reported - leading to more "publicity" so to speak.

    Looking at revenue per patient is a reasonably useless metric in the long term.
    Last edited by DocMcstuffins: 23/02/23
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
(20min delay)
Last
$2.28
Change
-0.020(0.87%)
Mkt cap ! $1.590B
Open High Low Value Volume
$2.34 $2.35 $2.27 $1.338M 582.5K

Buyers (Bids)

No. Vol. Price($)
55 9922 $2.28
 

Sellers (Offers)

Price($) Vol. No.
$2.29 10512 14
View Market Depth
Last trade - 15.40pm 12/07/2024 (20 minute delay) ?
PNV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.